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Abstract: Resistance to temozolomide (TMZ) is the main cause of death in glioblastoma multiforme
(GBM). The use of nanocarriers for drug delivery applications is one of the known approaches to
overcome drug resistance. This study aimed to investigate the possible effect of selenium–chitosan
nanoparticles loaded with TMZ on the efficacy of TMZ on the expression of MGMT, E2F6, and
RELA genes and the rate of apoptosis in the C6 cell line. Selenium nanoparticles (SNPs) were
loaded with TMZ and then they were coated by Eudragit® RS100 (Eud) and chitosan (CS) to prepare
Se@TMZ/Eud-Cs. Physicochemical properties were determined by scanning electron microscope
(SEM), energy-dispersive X-ray spectroscopy (EDAX), thermal gravimetric analysis (TGA), Fourier-
transform infrared spectroscopy (FTIR), and dynamic light scattering (DLS) methods. Se@TMZ/Eud-
Cs was evaluated for loading and release of TMZ by spectrophotometric method. Subsequently, SNPs
loaded with curcumin (as a fluorophore) were analyzed for in vitro uptake by C6 cells. Cytotoxicity
and apoptosis assay were measured by MTT assay and Annexin-PI methods. Finally, real-time
PCR was utilized to determine the expression of MGMT, E2F6, and RELA genes. Se@TMZ/Eud-Cs
was prepared with an average size of 200 nm as confirmed by the DLS and microscopical methods.
Se@TMZ/Eud-Cs presented 82.77 ± 5.30 loading efficiency with slow and pH-sensitive release
kinetics. SNPs loaded with curcumin showed a better uptake performance by C6 cells compared with
free curcumin (p-value < 0.01). Coated nanoparticles loaded with TMZ showed higher cytotoxicity,
apoptosis (p-value < 0.0001), and down-regulation of MGMT, E2F6, and RELA and lower IC50 value
(p-value < 0.0001) than free TMZ and control (p-value < 0.0001) groups. Using Cs as a targeting agent
in Se@TMZ/Eud-Cs system improved the possibility for targeted drug delivery to C6 cells. This
drug delivery system enhanced the apoptosis rate and decreased the expression of genes related to
TMZ resistance. In conclusion, Se@TMZ/Eud-Cs may be an option for the enhancement of TMZ
efficiency in GBM treatment.
Keywords: glioblastoma multiforme; temozolomide; selenium nanoparticle; Cs; Eud; RELA; MGMT;
E2F6
1. Introduction
Glioblastoma multiforme (GBM) is the most common, aggressive, and deadly pri-
mary brain tumor in adults, with a median survival of 12–15 months post diagnosis [1].
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The main cause of mortality in GBM patients is excessive drug resistance [2]. Although
temozolomide (TMZ) is an alkylating chemotherapy key agent for GBM treatment, there
is considerable resistance to this drug, which causes recurrence of the disease [3]. The
anti-cancer mechanism of TMZ is as follows: cell cycle suppression in the G2/M stage,
DNA damage, and consequently, GBM cells apoptosis [3,4]. This process ensues during
DNA replication by carrying a methyl group that attaches to guanine at the O6 and N7
positions, and adenine at the N3 position. These mismatched lethal base pairs can result
in single- and double-strand DNA breaks (DSB) that lead to cell apoptosis [5,6]. TMZ is a
class of imidazotetrazines [7–9] that is an alkylating agent, which is stable at acidic pH but
is rapidly converted to 3- methyl-(traiazan-1-yl) imidazole- 4- carboxamide (MTIC) at phys-
iological pH [7,8]. The MTIC methylates DNA, but it is not able to cross the blood–brain
barrier (BBB) and displays a low cell absorption, thus diminishing healing efficacy [10].
Furthermore, the molecular mechanisms in TMZ resistance have been identified. One of
the most significant cellular factors involved in TMZ resistance therapy is MGMT (O-6-
Methylguanine-DNA Methyltransferase) [11,12]. It is a 22 kD DNA repair enzyme that
destroys the methyl group in DNA. Therefore, MGMT is involved in chemotherapy resis-
tance due to its ability to eliminate the toxicity of alkylating agents, such as TMZ. MGMT
promoter methylation was associated with enhanced patients’ survival when they were
cured with alkylating agents like TMZ [13]. E2F6 is another key factor in TMZ resistance in
GBM patients. E2F6 enhances DSB repairability; thus, overexpression of E2F6 increases the
TMZ resistance [4]. EGFRvIII/AKT/NF-κB signaling pathway controls the E2F6 expression
level that is a direct target gene of NF-κB [14]. Binding the NF-κB complex to the MGMT
promoter leads to TMZ chemoresistance. NF-κB expression is excessive in glioma tissues
and inversely related to the overall survival (OS) of patients [15]. On the other hand, RELA
gene expresses p65 (RelA) which is a subunit of the NF-κB family. GBM has a high NF-κB
expression and affects many of the major GBM oncogenic pathways. TMZ therapy can
significantly activate the NF-κB signaling pathway in GBM [16]. It is shown that NF-κB
inhibitor with TMZ can create significant apoptosis in GBM via the p65 (RelA) protein [17].
Several strategies have been proposed to overcome resistance to cancer chemotherapies.
Nanocarriers have the potential to limit drug toxicity, achieve tumor localization, and
overcome drug resistance [18,19]. On the other hand, brain drug delivery and passing
the blood–brain barrier (BBB) are directly affected by particle size. Therefore, the size of
nanoparticles also plays a role in effective treatment [20,21]. In cancer treatment, selenium
compounds can be used to overcome drug resistance and recurrent cancer [22]. Moreover,
selenium nanoparticles (SNPs) display synergistic effects with their therapeutic cargo and
improve anticancer activity [23,24].
In this research we aimed to formulate a multicomponent, selenium nanoparticle-
based therapeutic for GBM patients. In order to achieve optimum efficacy and site-specific
drug delivery we employed chitosan and Eudragit® RS100 (Eud) in the formulation.
Chitosan (Cs) is a natural, non-toxic, cationic polymer with some favorable mucoadhesive
and anticancer properties, including the ability to induce apoptosis and targeted drug
delivery to tumors [25,26]. It is proven that the use of Cs enhances TMZ stability by loading
in Cs-based nanoparticles [10]. Eud, on the other hand, is a pH-dependent polymer that
can be dissolved in a medium with pH > 5.5 [27,28]. Since overexpression of MGMT,
E2F6, and RELA (NF-κB) genes with well-known mechanisms are involved in TMZ drug
resistance, the purpose of this study was to design and prepare an SNP coated with Eud-Cs
for TMZ delivery to a TMZ-resistant cell line (C6 cell line) [29]. The designations used
throughout the manuscript for the designed formulations are depicted in Figure 1. After
characterization and evaluation of the unloaded (empty) nanoparticles and nanodrug
particles, the effect of further delivery of TMZ was measured via expression levels of
MGMT, E2F6, and RELA genes and cell apoptosis compared to the control samples with
no nanocarriers.
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Figure 1. Designations and schemes of the formulations designed in current study. The work
flow of the synthesis of nanoparticles and their characterization can be summarized as follows:
In the first step of nanoparticle preparation, precipitation of selenium by ascorbic acid solution of
selenium dioxide was performed and the selenium nanoparticles (SNPs) were constructed. Surface
adsorption of TMZ on the selenium nanoparticles was achieved in the next step. Precipitation of
Eud on Se@TMZ was performed and then Se@TMZ/Eud was coated by chitosan (Cs) to prepare
Se@TMZ/Eud-Cs. Thereafter, characterization of Se@TMZ/Eud-Cs including morphology, size, zeta
potential, elemental composition, chemical structure and in vitro drug loading and release were
carried out.”-.-“ represents chitosan presence on the particles.
2. Materials and Methods
2.1. Reagents
The C6 cell line (rat GBM) was obtained from the Pasteur Institute of Iran (Tehran,
Iran). Dulbecco’s Modified Eagle’s Medium with 1000 mg/mL glucose (DMEMF12),
fetal bovine serum (FBS), penicillin-streptomycin solution (10,000 units/mL penicillin
and 10 mg/mL streptomycin in normal saline), phosphate buffered saline (PBS; pH 7.4),
and trypsin-EDTA (0.25% trypsin, 1 mM) were purchased from Biosera (Vienna, Austria).
Commercial Eud (Eudragit® RS100) was obtained from Evonik industries (Essen, Rhine–
Westphalia, Germany). TMZ, low molecular Cs, and other reagents and solvents were
purchased from Merck (Darmstadt, Hesse, Germany).
2.2. Nanoparticle Preparation
Initially, 55.5 mg of selenium dioxide was dissolved in 500 mL of deionized water by
stirring. Then, 387.2 mg of ascorbic acid was dissolved in 50 mL of deionized water and
it was added dropwise to the first solution with a stirring speed of 500 rpm [3]. During
the addition of the ascorbic acid solution, SNPs were formed, and the color of the solution
turned red. The red color suspension of SNPs was spun for about 1 h. In the following step,
10 mL of the suspension was added to 1 L of deionized water and 50 mL of TMZ solution
(5 mg/mL in deionized water) was added and stirred for 2 h. Next, Eud solution (20 mg in
10 mL of acetone) was subjoined gradually to the last suspension and it was stirred for 24 h
at 4 ◦C [30]. The sediment was separated by centrifugation at 20,000 rpm for a period of
30 min. In this step, Se@TMZ/Eud nanoparticles were prepared. In order to synthesize
Se@TMZ/Eud-Cs nanoparticles, 5 mL of the Cs solution (5 mg in 0.1 M acetic acid) was
added to the Se@TMZ/Eud suspension (before the centrifuge step) and placed on the
stirrer for 12 h [31]. The final Se@TMZ/Eud-Cs nanoparticles were obtained as explained
in the previous centrifugation step. Prepared nanoparticles were dried by freeze-drying
instrument and used for further analysis.
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2.3. Characterization of the Nanoparticles
Several techniques were employed to characterize the prepared nanoparticles. Se,
Se@TMZ/Eud, and Se@TMZ/Eud-Cs were observed under the scanning electron mi-
croscopy (FE-SEM, Tescan/Mira, Brno, Czech Republic) to evaluate the shape and surface
morphology of the nanoparticles. Moreover, the particle size, size distribution, and zeta po-
tential of the nanoparticles were assessed by DLS (Mastersizer 2000; Malvern Instruments,
Malvern, Worcestershire, UK). To investigate the surface elements of the final nanoparticle,
the EDAX method was used with a field-emission scanning electron microscope (FE-SEM,
Tescan/Mira, Brno, Czech Republic) coupled with an EDAX detector. The surface modifica-
tion of the nanoparticles in each step was studied by infrared (IR) spectroscopy recorded on
a Nicolet Magna IR-550 (Madison WI, USA) using KBr pellets. Thermal gravimetric analy-
sis (TGA) system (STA PT 1600, Linseis, Germany) with a temperature ramp of 5 ◦C/min
or 10 ◦C/min was employed under N2 atmosphere with a rate of 50 mL/min to determine
TGA curves of the SNPs.
2.4. Evaluation of Drug Content
To evaluate the loaded TMZ, an indirect method was used. For this, at the centrifuge
step of nanoparticle preparation, the supernatant was separated and evaluated. TMZ
content was measured by a UV–Vis spectrophotometer at 326 nm with using a calibration
curve [32]. TMZ loading efficiency and TMZ loading capacity of the nanoparticles were
calculated employing Equations (1) and (2), respectively:
% TMZ Loading efficiency = (Initial amount of TMZ − Amount of TMZ in supernatant)/(Initial amount of TMZ) × 100 (1)
% TMZ Loading capacity = (Initial amount of TMZ − Amount of TMZ in supernatant)/(Amount of final nanoparticles) × 100 (2)
2.5. Evaluation of Drug Release
Under sink condition, 2 mg of TMZ-loaded nanoparticles were poured into a dialysis bag
and 2 mL phosphate-buffered saline (PBS) was added to it. The closed bag was placed in a glass
beaker containing 20 mL PBS to set in a shaker incubator at 37 ◦C and 100 rpm. At this stage, two
BPS solutions with pH 7.4 and pH 5.0 were used. At the preschedule sampling time, 1 mL sample
was taken and 1 mL of fresh PBS was added to measure the absorbance value using a UV–Vis
spectrophotometer at the wavelength of 326 nm [33–35].
2.6. Evaluation of Cellular Uptake of Nanoparticles by Flow Cytometry
In order to evaluate the cellular uptake efficiency of Se@TMZ/Eud-Cs, curcumin (Cur) molecule,
which has intrinsic fluorescent properties, was used to label SNPs [31]. For the synthesis of
Se@Cur/Eud-Cs, 5 mL of Cur solution (1 mg/mL in acetone) was used instead of TMZ solution and
the other steps were performed as before. To evaluate cellular uptake of nanoparticles, C6 cells were
cultured in 6-well plates with a density of 5 × 105 and incubated for 24 h. Subsequently, cells were
treated with Cur and Se@Cur/Eud-Cs with the same concentration of Cur for 4 h. The cells were
then washed with PBS to remove the culture medium. Imaging was performed by flow cytometry
(flow cytometer Partec, Space Xenon/Argon laser, Sysmex Partec GmbH, Münster, Germany).
2.7. Cell Culture and Cell Viability Assay
C6 cell line (rat GBM) was stored in −70 ◦C. C6 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM F12) supplemented with 10% fetal bovine serum (FBS), 100 IU/mL strep-
tomycin, and 100 IU/mL penicillin, in an incubator at 37 ◦C, 5% CO2, and 95% humidity. Cell
passaging was done after 48 h using trypsin-EDTA (0.25%). Cell viability was evaluated by the MTT
assay for the Se@TMZ/Eud-Cs and Se@TMZ/Eud samples in comparison with free TMZ and control.
Cells were seeded at a frequency of 5000 cells per well (96-well plate). They adhered to the bottom
of the plate in an incubator at 37 ◦C after 24 h. Then, 200 µL of different concentrations of TMZ
(0–1200 µL) and TMZ-loaded SNPs with the same concentration of TMZ were treated for 48 h. In the
next step, 20 µL MTT (5 mg/mL) was added to each well. Cells were incubated for 4 h at 37 ◦C. To
remove the contents of the wells, 200 µL DMSO was added to each well and incubated for 20 min.
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Finally, they were centrifuged and the absorbance of the supernatant was determined at 570 nm with
the ELISA reader (STAT FAX 2100, Ramsey, MN 55303, USA).
2.8. Apoptosis Assay
The C6 cells (with a density of 5 × 105) were seeded in a 6-well plate and were then treated with
TMZ, Se@TMZ/Eud-Cs, and Se@TMZ/Eud with 200 µM concentration of TMZ for 48 h at 37 ◦C and
5% CO2. Untreated cells were used as the control group. In the following stage, the culture medium
was removed and cells were washed twice with PBS. 1 mL Annexin V-FITC/PI (BD Biosciences
cat: 51-66211E) was added to each well for 20 min at room temperature in darkness. Afterwards,
the solution was removed after adding 1 mL PBS to the wells, and C6 cells were analyzed by flow
cytometry (flow cytometer Partec, Space Xenon/Argon laser, Hamburg, Germany).
2.9. RNA Extraction and cDNA Synthesis
The C6 cells (with a density of 1 × 106) were cultured in each of the 10 cm2 plates. Af-
ter 24 h of seeding, cells were treated with different formulations, i.e., TMZ, Se@TMZ/Eud, and
Se@TMZ/Eud-Cs (all with the same concentration of 200 µM TMZ). After 48 h, RNA was extracted
with RiboEx reagent (GeneAll, #301-001) after removing the culture medium from the plates ac-
cording to the manufacturer’s instructions. Cells were lysed by adding 1 mL of RiboEx reagent.
After that, through washing with chloroform and ethanol (according to the manufacturer’s manual),
total RNA was obtained. Total RNA concentration and quantity (OD adsorption at 260 nm) were
measured using a Thermo Scientific™ NanoDrop 2000. By using gel electrophoresis, the quantity of
the extracted RNA was measured. cDNA synthesis was done with 1 µg of total RNA, by utilizing a
random hexamer primer and cDNA Synthesis Kit (Yekta Tajhiz Azma, Iran #YT4500) following the
manufacturer’s protocol.
2.10. Real-Time PCR
The primers for qPCR analysis for rat MGMT, E2F6, RELA, and Actb (as internal control)
genes were designed by Primer3 web-based server [36] and Integrated DNA Technologies (IDT)
(Coralville, IA, USA). Their specificity was tested with Primer-BLAST of the NCBI genome browser.
The used primer sequences are listed in Table 1. The mRNAs expression levels were carried out on a
Rotor-Gene 3000 system (Corbett Research, Sydney, Australia), using the synthetic primers and Real
Q Plus 2x Master Mix Green (Ampliqon, Denmark #A323402), according to the protocol provided by
the manufacturer. Eventually, a 2−∆∆ct method was used for gene expression analysis.
Table 1. The sequence of Real-Time PCR primers used in the study.
Gene Name Forward Primer (5′–3′) Reverse Primer (5′–3′) Annealing Tm (◦C) PCR Product Length
MGMT GACAGGTGTTATGGAAGCTG GGCTGCTAATTGCTGGTAAGA 58 71
E2F6 ATGTGTCGCTGGTCTACTTA ATGTGGTTCTTAGATTTCTTTTCC 56 178
RELA CGTGAGGCTGTTTGGTTTGAG GTCTTATGGCTGAGGTCTGGTC 62 109
Actb AGAGGGAAATCGTGCGTGAC AGGAAGGAAGGCTGGAAGAGA 60 187
2.11. Statistical Analysis
All data were presented as mean ± SD. All statistical analyses were performed using GraphPad
Prism v.8.4.3. Intergroup comparisons were made using ANOVA test followed by the Tukey method
and p < 0.05 was considered to be significant. All cell manipulation tests were performed in triplicate.
3. Results
3.1. Characterization of Nanoparticles
3.1.1. Morphological and Surface Properties
Morphological features and surface properties of prepared SNPs were investigated by the field
emission scanning electronen microscope (FE-SEM) instrument. Figure 2A confirmed the spherical
shape and uniform distribution of SNPs. The size of SNPs was approximately 150 nm (Figure 2A). An
approximate 20 nm increase in the size of the drug-loaded particles was observed after covering the
surface of SNPs with the Eudragit polymers (Figure 2B). The thickness of the coated layer increased
more in the final nanoparticles when compared with those obtained in the previous step. The size of
Se@TMZ/Eud-Cs particles was about 200 nm (Figure 2C).
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Figure 2. FE-SEM images of (A) SNPs, (B) Se@TMZ/Eud, and (C) Se@TMZ/Eud-Cs.
3.1.2. Evaluation by DLS and SBL
The SNPs and Se@TMZ/Eud-Cs were evaluated by the dynamic light scattering (DLS) method
and sparse Bayesian learning (SBL) calculation, which assists to reduce the agglomeration error,
particularly at the nanoscale. Consequently, the obtained particle size by this method is close to
the results obtained by SEM. As observed in Figure 3a,b, SNPs and Se@TMZ/Eud-Cs exhibited an
average diameter of 169 and 228 nm, respectively. These data are in agreement with the results
obtained by the SEM studies. The sharp peaks at Figure 3a,b present a narrow size distribution for
the mentioned nanoparticles. Furthermore, the zeta potential of SNPs and Se@TMZ/Eud-Cs were
investigated. The zeta potential value obtained for SNP was−20 mV (Figure 3c). As Figure 3d shows,
the positive zeta potential for Se@TMZ/Eud-Cs (+32 mV) demonstrated surface modifications of
Se@TMZ/Eud-Cs by Cs.
Figure 3. Size distribution and zeta potential were obtained by using DLS and SBL. (a) DLS evaluation of the number of SNPs,
(b) DLS evaluation of the number of Se@TMZ/Eud-Cs, (c) Zeta potential of SNPs, (d) Zeta potential of Se@TMZ/Eud-Cs.
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3.1.3. Validity Measurement by EDAX Assay
Se@TMZ/Eud-Cs were evaluated by the energy-dispersive X-ray analysis (EDAX) method to
determine elemental composition (Figure 4). It was found that the elements of selenium (Se), carbon
(C), oxygen (O), nitrogen (N), and chlorine (Cl) were present in final nanoparticles with the atomic
ratio of 0.1, 48.4, 36.1, 13.8, and 0.7%, respectively. These data, therefore, re-assured that SNPs were
coated by Cs and Eud on the surface.
Figure 4. EDAX spectra obtained for Se@TMZ/Eud-Cs.
3.1.4. Fourier Transform Infrared Spectroscopy (FTIR) Assay
FTIR confirmed the formation of Se@TMZ/Eud-Cs. Figure 5A depicts the composite sample
of Se@TMZ/Eud-Cs. All the index peaks of ingredients as SNPs, TMZ, Cs, and Eud can be seen in
this figure. It can be attributed to stretching and bending vibration of Se–O at 1105 and 470 cm−1,
respectively, as they can be observed in Figure 5B. O–H stretch from 3300–2500 cm−1 and C=O
stretch from 1760–1690 cm−1 confirmed the presence of carboxylic acid functional groups in Eud
(Figure 5C). Those stretching vibrations were pointed to Eud presence in the Se@TMZ/Eud-Cs
composition. In addition, the functional indicator groups of Cs as C–N and C=O are visible in the
absorption spectra of stretching vibration at 1451 and 1733 cm−1, respectively (Figure 5D). In the TMZ
spectrum, the N=N vibration peak at 1595 cm−1 appears in Figure 5E. The structure of temozolomide
in Se@TMZ/Eud-Cs can be detected by FTIR by N=N stretching vibration at 1471 cm−1, which
decreased due to the presence of metal complexes.
3.1.5. TGA Analysis
The modified surface of Se@TMZ/Eud-Cs was further confirmed by TGA analysis under a
constant N2 flow (Figure 6). Results showed that Se@TMZ/Eud-Cs and Se@TMZ/Eud lost up to
56.45% and 67.95% of their total mass at 798.1 ◦C, while Se@TMZ and SNPs only lost up to 68.3% and
94.50% of their mass at the same temperature, respectively. The low weight loss in the thermogram
of SNPs indicated the evaporation of the residual solvent, adsorbed water, and NO-functional group
on these nanoparticles. The thermogravimetry of Se@TMZ/Eud-Cs, Se@TMZ/Eud, and Se@TMZ
had higher carbon contents than SNPs related to the high drug loading of TMZ. TMZ loading in the
nanoparticles was influenced by different factors, such as nanoparticle surface charge, electrostatic
attraction between TMZ, SNPs, and drug encapsulation by Eud and Cs-coated particles. These factors
affected Se@TMZ/Eud-Cs to get high payload as shown in Figure 6. While Se@TMZ/Eud showed
a lower TMZ loading than Se@TMZ/Eud-Cs, it could be a point to the importance of Cs for drug
capture in nanoparticles. The difference in weight loss between Se@TMZ/Eud and Se@TMZ/Eud-Cs,
and between Se@TMZ and Se@TMZ/Eud can be a hint to the decomposable nature of Eud and Cs
layer, respectively.
Nanomaterials 2021, 11, 1704 8 of 18
Figure 5. FTIR spectra of: (A) Se@TMZ/Eud-Cs, (B) SNPs, (C) Eud, (D) Cs, and (E) TMZ.
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Figure 6. TGA analysis of the formulated nanoparticles under a constant N2 flow. Se@TMZ/Eud-Cs
and Se@TMZ/Eud lost up to 56.45% and 67.95% of their total mass at 798.1 ◦C, while Se@TMZ and
SNPs only lost up to 68.3% and 94.50% of their mass at the same temperature, respectively.
3.1.6. Drug Loading and In Vitro Release of Nanoparticles
TMZ loading in the nanoparticles was influenced by different factors, such as nanoparticle
surface charge, electrostatic attraction between TMZ, SNPs, and drug encapsulation by Eud and
Cs-coated particles. These factors affected Se@TMZ/Eud-Cs to get high payload as shown in Table 2.
While Se@TMZ/Eud showed a lower TMZ loading than Se@TMZ/Eud-Cs, it could be a point to the
importance of Cs for drug capture in nanoparticles.
Table 2. TMZ loading profile. Data are represented as mean ± SD, n = 3.
Nanoparticles TMZ Loading Efficiency (%) TMZ Loading Capacity (%)
Se@TMZ/Eud-Cs 82.77 ± 5.30 37.5 ± 4.43
Se@TMZ/Eud 61.70 ± 3.65 15.71 ± 3.43
The in vitro release profiles of TMZ from Se@TMZ/Eud and Se@TMZ/Eud-Cs in two buffer
media with pH = 5 and 7.4 are shown in Figure 7. It was detected that drug release was pH-dependent
because of the significantly higher TMZ release at pH = 5 compared to pH = 7.4 (p-value < 0.0001).
Se@TMZ/Eud release profile showed that TMZ was burst-released in the first 5 h and faster than
Se@TMZ/Eud-Cs. While Se@TMZ/Eud-Cs prevented burst release significantly in the early hours
due to Cs coating (p-value < 0.0001). Therefore, in view of these observations, the cancer cells have
an acidic pH [37]; this drug delivery system has helped targeted TMZ delivery to brain cancer cells
due to pH sensitivity of the nanoparticles and TMZ can be released in a predictable and required
manner (Figure 7).
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Figure 7. In vitro TMZ release profile from Se@TMZ/Eud and Se@TMZ/Eud-Cs at pH = 5 and
7.4. Both coated SNPs loaded with TMZ released significantly more concentration of drug at pH
5 compared to pH 7.4 (p-value < 0.0001), indicating pH-dependence of drug-release. Moreover,
at all specified time points, Se@TMZ/Eud-Cs exhibited a dramatically higher cumulative release
of TMZ than Se@TMZ/Eud-Cs (p-value < 0.0001). Data are represented as mean ± SD, n = 3.
*** p-value < 0.0001.
3.1.7. Cellular Uptake
TMZ has no measurable autofluorescence activity [38]. Therefore, the amount of cellular uptake
was measured using labeled Se@Cur/Eud-Cs with curcumin [31]. The results showed a significantly
higher uptake of Se@Cur/Eud-Cs compared to free Cur (p-value < 0.01) in C6 cells after 4 h with
90.35 ± 1.65 and 72.05 ± 1.95 rates of positive fluorescent cells, respectively (Figure 8).
Figure 8. Cellular uptake of SNPs. Curcumin (Cur) molecule, which has intrinsic fluorescent properties, was used to label
SNPs. For the synthesis of Se@Cur/Eud-Cs, 5 mL of Cur solution (1 mg/mL in acetone) was used instead of TMZ solution
and cellular uptake of Cur and Se@Cur/Eud-Cs was evaluated by flow cytometry. The results showed higher uptake of (a)
Se@Cur/Eud-Cs rather than (b) free Cur (p-value < 0.01) in C6 rat glioblastoma cells after 4 h treatment. (c) Cellular uptake
of Se@Cur/Eud-Cs compared to free Cur in the C6 cells after 4 h treatment. Data are represented as mean ± SD, n = 3.
** p-value < 0.01.
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3.2. Cytotoxicity Studies
Free TMZ showed a dose-dependent inhibitory effect on the viability of C6 cells after 48 h treat-
ment, which was same as SNP loaded with TMZ. According to the MTT assay results, Se@TMZ/Eud-
Cs and Se@TMZ/Eud were dramatically more effective on increasing cytotoxicity (p-value < 0.0001)
with significantly lower IC50 value (205.76 ± 8.69 and 579.26 ± 6.47, respectively) compared with
free TMZ (918.50 ± 8.64) (Figure 9).
Figure 9. (A,B) Two different representation of the effects of Free TMZ in comparison with
Se@TMZ/Eud and Se@TMZ/Eud-Cs loaded with the same concentration of TMZ on the cell cytotox-
icity of C6 rat glioblastoma cells after 48 h. The cells were treated with different concentrations of the
samples for 48 h. The IC50 value of TMZ, Se@TMZ/Eud, and Se@TMZ/Eud-Cs were 918.50 ± 8.64,
579.26 ± 6.47 and 205.76 ± 8.69 µM, respectively. Data are represented as mean ± SD, n = 3.
3.3. Apoptosis Assay
As depicted in Figure 10, although early apoptosis was induced significantly in both of the
cell groups treated with coated SNPs containing 200 µM TMZ (p-value < 0.0001) and free TMZ with
the same concentration (p-value < 0.01) compared to the control, late apoptosis was increased just
by the influence of the nanoparticles (p-value < 0.0001). Moreover, a comparison of free TMZ and
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Se@TMZ/Eud-Cs showed notably higher induction of early and late apoptosis (p-value < 0.0001).
However, in cells treated with Se@TMZ/Eud, no significant difference was seen in the induction of
early apoptosis (Figure 10 and Table 3).
Figure 10. Effect of TMZ, Se@Cur/Eud, and Se@Cur/Eud-Cs on cell apoptosis. Untreated cells
were employed as a control. (a) Stained cells (Q1, AnnexinV +/P I−), (Q2, AnnexinV +/PI +),
(Q3, AnnexinV −/PI +), and (Q4, AnnexinV −/PI −) are identified as necrotic, delayed-phase of
apoptosis, primary-phase of apoptosis, and alive cells, respectively. (b) SNPs loaded with TMZ
induced significantly higher apoptosis than free TMZ (p-value < 0.0001) compared to the control.
Date expressed as mean ± SD, n = 3. * p value < 0.05, ** p value < 0.01, *** p value < 0.0001.
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Control 94.91 ± 2.39 1.96 ± 0.35 1.8 ± 0.24 1.14 ± 0.57
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Se@TMZ/Eud 70.72 ± 2.20 5.73 ± 0.50 8.18 ± 0.68 14.52 ± 2.63
Se@TMZ/Eud-Cs 58.86 ± 3.16 2.18 ± 0.27 19.16 ± 0.85 22.88 ± 4.98
3.4. Gene Expression Level Assay
Gene expression levels of MGMT, E2F6, and RELA genes after 48 h of treatment with TMZ,
Se@TMZ-Eud, and Se@TMZ-Eud-Cs showed that MGMT mRNA level increased in TMZ treated cells
significantly (p < 0.05) compared to the untreated group. Treatment with Se@TMZ-Eud and Se@TMZ-
Eud-Cs decreased MGMT notably (p < 0.05 and p < 0.01 respectively). Cs had more influence on the
reduction of the MGMT expression. RELA mRNA level increased in TMZ-treated cells compared
to control cells. RELA mRNA level reduced in both Se@TMZ-Eud- and Se@TMZ-Eud-Cs-treated
groups significantly (p < 0.05) compared with the TMZ treated group. E2F6 mRNA level remarkably
increased with Se@TMZ-Eud and decreased with Se@TMZ-Eud-Cs compared to the TMZ-treated
group (p < 0.05) (Figure 11).
Figure 11. Expression levels of MGMT, E2F6, and RELA genes. (a) MGMT mRNA level significantly
increased in TMZ treatment cells vs. untreated group. Treatment with Se@TMZ-Eud and Se@TMZ-
Eud-Cs decreased MGMT significantly. (b) RELA mRNA level significantly reduced in Se@TMZ-Eud-
and Se@TMZ-Eud-Cs-treated groups vs. TMZ-treated group. (c) E2F6 mRNA level significantly
increased with Se@TMZ-Eud and decreased with Se@TMZ-Eud-Cs vs. TMZ-treated group. Data are
presented as mean ± SD, n = 3. * p < 0.05 and ** p < 0.01.
4. Discussion
Resistance to TMZ is a major cause of recurrence of GBM, resulting in high mortality of GBM
worldwide [2,8]. The molecular mechanisms involved in TMZ resistance in GBM patients have been
described [39,40]. Therefore, the effectiveness of anti-cancer drugs could be improved by utilizing
approaches to control these molecular factors. Delivering the effective concentrations of therapeutic
agents to tumors is a strategic factor in increasing cancer treatment efficiency. Today, nanocarriers are
used as potential vectors in delivering agents to cancers, such as GBM [41,42]. In this study, we used
Se@TMZ/Eud-Cs nanoparticles to deliver TMZ to C6 cells.
SNPs were prepared by precipitation method and coated with Eud and Cs after TMZ loading
for targeted brain delivery in the C6 cell line. Formulated Se@TMZ/Eud-Cs were investigated
for intracellular delivery of TMZ and expression of MGMT, E2F6, and RELA genes in C6 cells.
Monodispersed SNPs with a particle size of about 200 nm were successfully prepared. As showed
in Figure 2A SNPs revealed spherical shape and narrow size distribution. After coating the SNPs
with Eud and Cs, Se@TMZ/Eud and Se@TMZ/Eud-Cs displayed a thin layer on the nanoparticle
surface, which increased the particle size (Figure 2B,C). As was reported in several studies, chemical
preparation of SNPs can produce spherical SNPs in the size range of 30–200 nm [43–45]. Moreover,
DLS results with SLB calculation confirmed the SEM data for the SNPs and Se@TMZ/Eud-Cs. As
depicted in Figure 3a,b SNPs and Se@TMZ/Eud-Cs displayed sharp peaks at 169 and 228 nm,
respectively. This is also in agreement with the SEM results and attests a narrow size distribution.
Zeta potential of empty SNPs was measured to be −20 mV [46], which increased to +32 mV due
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to the adsorption of positively charged Cs. A previous study by Daryasari et al. showed the same
results for a different type of nanoparticle coated with Cs [31].
EDAX analysis of the Se@TMZ/Eud-Cs confirmed surface modifications of SNPs with different
compositions of different molecules. As shown in Figure 5 the selenium, carbon, oxygen, nitrogen,
and chlorine peaks were found with the atomic ratios of 0.1, 48.4, 36.1, 13.8, and 0.7 (%), respectively.
Carbon, oxygen, nitrogen elements are usually found in most compounds such as Cs, Eud, and TMZ.
Appearance of a chlorine peak in the EDAX spectrum could be proof that Eud was located on the
surface of Se@TMZ/Eud-Cs.
As pointed out in the Results section, the structure of Se@TMZ/Eud-Cs was confirmed by the
FTIR method. The FTIR spectrum of Se@TMZ/Eud-Cs was compared with the free compound as
Cs, Eud, and TMZ. Figure 5A showed the composite sample of Se@TMZ/Eud-Cs. In Figure 5B,
the results of SNPs studies by FTIR are shown. However, some peaks including C=O and Se-O
were detected. These data attest the existence of some entrapment of started material, e.g., SeO2
and ascorbic acid by the SNPs [37]. In Figure 5C,D, results of Eud and Cs analysis are depicted.
All the index peaks for Eud and Cs as C=O and C=O stretching, respectively, were found in the
absorption spectra of Se@TMZ/Eud-Cs. Furthermore, the spectrum of TMZ was identified by N=N
vibration peak at 1595 cm−1 (Figure 5E). It can be detected by N=N stretching vibration at 1471 cm−1
in Se@TMZ/Eud-Cs, which was reduced by the presence of metal complexes [47].
TGA was used for further analysis of the final structure of Se@TMZ/Eud-Cs and its compo-
sitions in the later steps. As mentioned before, SNP only lost up to 94.50% of its mass at 798.1 ◦C.
This low mass reduction is related to the evaporation of the residual solvent and adsorbed water.
SNPs do not have any functional groups, however, as pointed above, a little residue of SeO2 and
ascorbic acid in SNPs were burned here. A sharp decrease of Se@TMZ/Eud-Cs, Se@TMZ/Eud and
Se@TMZ mass between 70 to 130 ◦C was indicative of high loading of TMZ in these nanoparticles.
This assumption could be supported by the fact that the boiling point of TMZ was detected to be
about 212 ◦C. Therefore, TMZ was evaporated gradually till 210 ◦C and after that, all the three
formulations of loaded TMZ nanoparticles did not show any mass decrease. Burning of organic
material happened in the temperature range of 300–650 ◦C. Consequently, the removal of Cs and
Eud should be seen in this range. The second sharp decline in Se@TMZ/Eud-Cs and Se@TMZ/Eud
masses were confirmed by the elimination of Cs and Eud compositions from these formulations. The
difference in the mass decline between Se@TMZ/Eud-Cs and Se@TMZ/Eud was an evidence of the
extra layer of Cs on Se@TMZ/Eud-Cs.
Most of the studies related to the TMZ stability deal with the chemical modification of this
drug. This demonstrates that the prepared polymeric nanoparticles were able to protect TMZ from
hydrolysis. The significant impact of the nanoparticles in preserving TMZ from hydrolysis is evident.
Free TMZ is quickly hydrolyzed to the inactive metabolites during the time between the sample
preparation and the contact with the media, which leads to its inactivation [10]. Our cellular uptake
results suggest that Cs-coated nanoparticles improved targeted delivery, followed by an increase
in cellular uptake and cytotoxicity of this drug. Cells treated with SNPs loaded with TMZ had an
upper death potential compared to those treated with TMZ, especially in treatment with higher
concentrations. A recent study demonstrated that the combination of Cs, biotin, and TMZ can
enhance the biological effects of TMZ [48]. In our study, similarly, the Cs compound decreased IC50
and increased cell apoptosis compared to TMZ in the C6 cells. This could be due to the ability of
Cs to interact with cell surface macromolecules and increase cellular uptake. Cs is widely used in
drug nanocarriers to improve drug loading, sustained release, cellular uptake, and drug targeting.
Furthermore, the positive charge of Cs in the nanoparticles is effective in adsorption to target cells [49].
The formulated Cs nanoparticles demonstrated acceptable results in the treatment of some
brain diseases, such as glioma, Parkinson’s, and Alzheimer’s [50]. Se@TMZ/Eud-Cs significantly
improved the stability of TMZ at acidic and neutral pH by reducing IC50. By the treatment of the
C6 cells with Se@TMZ/Eud and Se@TMZ/Eud-Cs, after 48 h, the expression of main genes in drug
resistance, such as MGMT and RELA, was decreased significantly compared with TMZ treatment.
Treatment with TMZ leads to MGMT over-expression. Other researcher groups showed similar
up-regulation [51]. Our study showed that presence of Cs in the nanodrugs is more effective in
reducing gene expression compared with the formulations with no Cs. The decreased expression may
lead to decreased therapeutic resistance. Therefore, it seems that nanodrugs will have a significant
effect on reducing resistance by affecting their signaling pathways. However, more studies are
needed to investigate the effect of our nanodrug on TMZ resistance. Regarding E2F6 expression, an
increase in gene expression was observed for Se@TMZ/Eud formulation. Although E2F6 expression
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for treatment with Se@TMZ/Eud-Cs was reduced similarly to MGMT and RELA, it is possible that
the presence of Cs cells was effective on the reduction of the E2F6 expression.
One of the known mechanisms of inducing TMZ resistance by MGMT is through RELA. RELA
has a role in inducing MGMT gene expression [52]. DNA damage by TMZ activates NF-κB. Therefore,
significant increase in E2F6 expression and promoting GBM cell survival leads to TMZ resistance.
Previous studies have shown that E2F6, E2F7, and E2F8 play a key role in repairing damaged DNA
in cells treated with a DNA degradation agent and increase resistance to chemotherapy drugs and
cell survival. These findings suggest that inhibition of E2F6 is a strategy for the development of
therapies. On the other hand, evaluating E2F6 expression can be useful as a biomarker. Research
findings indicate that suppression of E2F6 by inactivating NF-κB can increase TMZ sensitivity [4].
One study showed that prolonged exposure to TMZ might increase resistance and the malignant
phenotype in the malignant glioma cells [51]. Similarly, our gene expression analysis showed that
TMZ increased MGMT gene expression level after 48 h. Another study reported that increased
activity of the PI3K/AKT signaling pathway in GBM-induced TMZ resistance because this increased
activity caused the NF-κB p65 transcript to increase the expression of some genes, such as MGMT [52].
Another study reported that the signaling pathway (MEK)-(ERK)-(MDM2)-p53 is involved in the
MGMT gene expression [53]. Authors postulated that the inhibition of MEK and ERK activates P53
and reduces the MGMT gene expression and leads to induce sensitivity of glioma cells to TMZ. The
findings indicate that targeting the MEK-ERK-MDM2-p53 pathway in combination with TMZ could
be a new treatment and a promising strategy in GBM treatment [53]. On the other hand, NF-κB is
known as an important factor in MGMT transcription independent of the MGMT methylation status.
It has previously been shown that a high level of NF-κB promotes GBM alkylating agent-based
chemotherapy resistance. This resistance is associated with the activation of gene transcription. The
results suggest that cell exposure to the alkylating agent activates NF-κB and increased MGMT level.
Therefore, NF-κB inhibitors may help to overcome the chemical resistance induced by alkylating
chemotherapy [54]. There is a direct relationship between NF-κB/p65 and MGMT. There are two
NF-κB binding sites in the MGMT promoter region, which may indicate that NF-κB is an important
transcription factor in the regulation of MGMT transcription. Inhibition of NF-κB can reduce MGMT
gene expression [52]. Therefore, NF-κB/MGMT pathway regulation appears to be a new treatment
strategy to overcome TMZ resistance in GBM. On the other hand, the NF-κB pathway is also involved
in inhibiting apoptosis. GBM cells express high levels of BCL2 anti-apoptotic family proteins, such as
Bcl-2 and Bcl-xL, which may make these cells resistant to apoptosis. Inhibition of NF-κB expression
can inhibit Bcl-2 expression and enhance Bax expression, thereby causing apoptosis [49]. The gene
expression and apoptosis results showed that treatment by nanoparticles including Cs has acceptable
effects. One of the reasons for the increase in the antitumor activity of Cs-containing nanoparticles is
its positive charge and stability in the acidic environment of tumors.
5. Conclusions
Characterization of the Se@TMZ/Eud-Cs formulations showed that our designed nanodrug
properties are promising. Its cellular uptake is suitable for drug delivery applications. Compared
to the free form of the drug (TMZ), Se@TMZ/Eud-Cs formulation is more efficient in inducing
cytotoxicity, apoptosis, and regulation of resistance-related genes, including MGMT, RELA, and E2F6.
Therefore, it seems that using a suitable nanocarrier, such as Se@TMZ/Eud-Cs, can be effective in
increasing anti-cancer effects and reducing therapeutic resistance of the conventional anti-cancer
agents such as TMZ for GBM treatment in the future.
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